314 related articles for article (PubMed ID: 21651484)
1. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria.
Pagès JM; Amaral L; Fanning S
Curr Med Chem; 2011; 18(19):2969-80. PubMed ID: 21651484
[TBL] [Abstract][Full Text] [Related]
2. Efflux pumps of gram-negative bacteria, a new target for new molecules.
Pagès JM; Sandrine AF; Mahamoud A; Bolla JM; Davin-Regli A; Chevalier J; Garnotel E
Curr Top Med Chem; 2010; 10(18):1848-57. PubMed ID: 20615189
[TBL] [Abstract][Full Text] [Related]
3. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.
Nikaido H; Pagès JM
FEMS Microbiol Rev; 2012 Mar; 36(2):340-63. PubMed ID: 21707670
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria.
Pagès JM; Amaral L
Biochim Biophys Acta; 2009 May; 1794(5):826-33. PubMed ID: 19150515
[TBL] [Abstract][Full Text] [Related]
5. Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria.
Wang Y; Venter H; Ma S
Curr Drug Targets; 2016; 17(6):702-19. PubMed ID: 26424403
[TBL] [Abstract][Full Text] [Related]
6. The development of efflux pump inhibitors to treat Gram-negative infections.
Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M
Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793
[TBL] [Abstract][Full Text] [Related]
7. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective.
Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors.
Vila J; Martínez JL
Curr Drug Targets; 2008 Sep; 9(9):797-807. PubMed ID: 18781925
[TBL] [Abstract][Full Text] [Related]
9. Multidrug efflux pumps of Gram-positive bacteria.
Schindler BD; Kaatz GW
Drug Resist Updat; 2016 Jul; 27():1-13. PubMed ID: 27449594
[TBL] [Abstract][Full Text] [Related]
10. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.
Lomovskaya O; Bostian KA
Biochem Pharmacol; 2006 Mar; 71(7):910-8. PubMed ID: 16427026
[TBL] [Abstract][Full Text] [Related]
11. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates.
Mahamoud A; Chevalier J; Baitiche M; Adam E; Pagès JM
Microbiology (Reading); 2011 Feb; 157(Pt 2):566-571. PubMed ID: 21071494
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review on pharmacology of efflux pumps and their inhibitors in antibiotic resistance.
Thakur V; Uniyal A; Tiwari V
Eur J Pharmacol; 2021 Jul; 903():174151. PubMed ID: 33964293
[TBL] [Abstract][Full Text] [Related]
13. The hydrophobic trap-the Achilles heel of RND efflux pumps.
Aron Z; Opperman TJ
Res Microbiol; 2018; 169(7-8):393-400. PubMed ID: 29146106
[TBL] [Abstract][Full Text] [Related]
14. Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps.
Duffey M; Jumde RP; da Costa RMA; Ropponen HK; Blasco B; Piddock LJV
ACS Infect Dis; 2024 May; 10(5):1458-1482. PubMed ID: 38661541
[TBL] [Abstract][Full Text] [Related]
15. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance.
Blair JM; Richmond GE; Piddock LJ
Future Microbiol; 2014; 9(10):1165-77. PubMed ID: 25405886
[TBL] [Abstract][Full Text] [Related]
16. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery.
Schweizer HP
Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346
[TBL] [Abstract][Full Text] [Related]
17. Alkylaminoquinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates.
Malléa M; Mahamoud A; Chevalier J; Alibert-Franco S; Brouant P; Barbe J; Pagès JM
Biochem J; 2003 Dec; 376(Pt 3):801-5. PubMed ID: 12959639
[TBL] [Abstract][Full Text] [Related]
18. Measuring the activity of active efflux in gram-negative bacteria.
Webber MA; Coldham NG
Methods Mol Biol; 2010; 642():173-80. PubMed ID: 20401594
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors.
Moir DT; Opperman TJ; Aron ZD; Bowlin TL
Drug Discov Today; 2021 Sep; 26(9):2173-2181. PubMed ID: 33845218
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.
Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF
mBio; 2020 Sep; 11(5):. PubMed ID: 32934086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
